NCGS focuses only on complex areas of clinical development; oncology-hematology, infectious disease, critical care and CNS in both adult and pediatric populations. Since 1984, NCGS has 58 approved drug, biologic, diagnostic, and device products and has had no FDA Warning Letters / 483s.
Our unique business model has been specifically designed to overcome the challenges inhibiting our industry today. We employ only 10 plus year tenured staff with cross-functional expertise in clinical operations, regulatory compliance and auditing. Our global footprint spans North America, Latin America, Europe, Asia Pacific Rim, and Australia.